Compare Becton Dickinson and Co (BDX) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Nomura Holdings Inc — how do they compare? Becton Dickinson and Co trades at $156.39 (market cap $41.51B), while Nomura Holdings Inc trades at $10.01 (market cap $28.06B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Nomura Holdings Inc pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| BDX | NMR | |
|---|---|---|
Market Cap | $41.51B | $28.06B |
Sector | Health | Financials |
52-Week High | $185.39 | $9.75 |
52-Week Low | $135.49 | $6.30 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Nomura Holdings (NMR) trades at $9.62, down 0.41% on the day, with a P/E of 13.08 suggesting reasonable valuation. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Recent earnings show mixed results with one beat and two misses, but annual revenue grew to $1.66 trillion with a robust 20.49% net margin. The company posted record annual profit of $340.74 billion in 2025, driving positive sentiment around its wholesale and wealth management segments.
Nomura presents a compelling value opportunity with strong profitability metrics and expansion in core businesses, though recent earnings misses and negative operating cash flow pose near-term concerns. The bullish analyst consensus and technical setup support upside potential, but investors should monitor integration costs from recent acquisitions and debt levels that have increased to 26.25% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
